Enovis Co. (NYSE:ENOV) Short Interest Update

Enovis Co. (NYSE:ENOV) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 5,000,000 shares, a decline of 5.1% from the January 15th total of 5,270,000 shares. Based on an average daily volume of 810,800 shares, the short-interest ratio is presently 6.2 days. Approximately 9.0% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, Needham & Company LLC reissued a “buy” rating and issued a $65.00 target price on shares of Enovis in a research report on Thursday, November 7th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $64.83.

Hedge Funds Weigh In On Enovis

Several institutional investors have recently added to or reduced their stakes in the stock. River Road Asset Management LLC acquired a new position in shares of Enovis in the third quarter valued at approximately $51,341,000. Hood River Capital Management LLC purchased a new stake in shares of Enovis in the fourth quarter valued at about $29,024,000. Paradigm Capital Management Inc. NY boosted its holdings in shares of Enovis by 2,566.0% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 533,200 shares of the company’s stock valued at $23,397,000 after acquiring an additional 513,200 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Enovis during the fourth quarter worth about $16,407,000. Finally, Royce & Associates LP lifted its position in Enovis by 16.8% in the third quarter. Royce & Associates LP now owns 2,403,685 shares of the company’s stock valued at $103,479,000 after purchasing an additional 346,317 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Trading Up 0.6 %

NYSE ENOV opened at $44.55 on Thursday. Enovis has a one year low of $38.27 and a one year high of $65.03. The firm has a market cap of $2.53 billion, a PE ratio of -20.34 and a beta of 1.94. The firm’s fifty day moving average is $45.21 and its two-hundred day moving average is $44.33. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.